NCT06338293

Effects of Inclisiran Combined With Statins on the Morphology of Coronary Vulnerable Plaques

Name: Clinical Trial NCT06338293
Creator: Nanjing First Hospital, Nanjing Medical University
Keywords: Coronary Artery Disease, Inclisiran sodium, Phase 4, drug, clinical trial

Using OFR Software to Observe the Effects of Inclisiran Combined With Statins on the Morphology and Vascular Function of Coronary Vulnerable Plaques

Nanjing First Hospital, Nanjing Medical University·Phase 4·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Coronary Artery Disease
Drug/Device/Intervention: Inclisiran sodium
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: Nanjing First Hospital, Nanjing Medical University

Timeline & enrollment

Phase: Phase 4
Start date: Mar 01, 2024
End date: May 01, 2025
Enrollment: 40 participants

Primary outcome

The change rate of the thinnest fibrous cap of vulnerable plaque at the target vascular lesion from baseline to one-year follow-up(△ FCT%)

Summary

Effects of inclisiran + statins vs. statins on the morphology and vascular function of coronary vulnerable plaques, in order to provide a better treatment and more detailed imaging basis for the treatment of coronary vulnerable plaques.

ICD-10 classifications

Cardiovascular disease, unspecifiedAtherosclerotic cardiovascular disease, so describedAtherosclerotic heart diseaseAbnormal findings on diagnostic imaging of heart and coronary circulationCoronary vasodilators, not elsewhere classified

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06338293
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06338293 through Pure Global AI's free database. This Phase 4 trial is sponsored by Nanjing First Hospital, Nanjing Medical University and is currently Not yet recruiting. The study focuses on Coronary Artery Disease. Target enrollment is 40 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.